Roche’s Columvi shows durable three-year overall survival edge over Rituxan in phase III STARGLO trial

Roche Holding AG reported that its bispecific antibody Columvi, known scientifically as glofitamab, delivered a sustained overall survival advantage at the three-year follow-up of the pivotal phase III STARGLO study in patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplant. The updated data show that the Columvi combination with gemcitabine and oxaliplatin more than doubled median overall survival compared with the long-standing Rituxan-based comparator regimen, reinforcing its position as one of the most potent off-the-shelf immunotherapy options in aggressive B-cell lymphoma. The findings arrive at a critical moment for Roche as the company continues to defend its leadership in hematologic oncology against a crowded field of CAR-T therapies, antibody-drug conjugates, and next-generation bispecific antibodies.

The three-year dataset from STARGLO confirms that clinical benefit with Columvi is not only rapid but durable. Median overall survival in the experimental arm reached 25.5 months versus 12.5 months in the Rituxan plus GemOx control arm, with a statistically significant hazard ratio that supports a robust reduction in the risk of death. Progression-free survival also remained markedly superior, reflecting sustained disease control rather than short-lived tumor responses. Importantly, these survival gains were achieved in a population with historically poor outcomes, where treatment options after first relapse have long been limited, especially for patients who are not candidates for intensive transplantation.

How does the three-year STARGLO survival data change expectations for non-transplant relapsed diffuse large B-cell lymphoma patients?

For transplant-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma, the three-year STARGLO update fundamentally shifts survival expectations. Historically, this group has faced median overall survival measured in months rather than years, with limited access to curative therapies. The durable survival curve now reported with Columvi plus gemcitabine and oxaliplatin suggests that a meaningful subset of patients may achieve long-term remission without the need for autologous transplantation or complex cellular therapies. Subgroup analyses showed that in second-line patients, more than half remained alive at 36 months, and median overall survival was not yet reached at the time of analysis, indicating prolonged benefit in earlier relapse settings.

The clinical implication is that Columvi is no longer viewed simply as a short-term disease-control agent but as a therapy with potential curative intent in selected patients. Because Columvi is administered as a fixed-duration intravenous regimen rather than a continuous treatment, patients also benefit from defined treatment periods rather than indefinite therapy. This reduces cumulative toxicity, long-term financial burden, and logistical strain on infusion centers, factors that weigh heavily in real-world oncology practice.

From a mechanistic standpoint, Columvi’s dual targeting of CD20 on B-cells and CD3 on T-cells enables direct immune synapse formation and tumor cell killing. This mechanism has proven powerful even in heavily pretreated disease. The three-year STARGLO data now demonstrate that this immune-mediated activity translates into long-lasting survival at the population level rather than merely transient responses.

What safety and tolerability trends emerged with longer Columvi exposure in the phase III STARGLO population?

Extended follow-up from STARGLO showed that the safety profile of Columvi remained consistent with earlier analyses and with what is known about T-cell–engaging bispecific antibodies. Cytokine release syndrome remained the most frequently observed immune-related adverse event, but the majority of episodes were low grade and clinically manageable with established mitigation protocols. No new late-emerging toxicities were identified over the three-year follow-up period, an important finding as long-term immune modulation sometimes raises concerns about delayed safety effects.

Other treatment-emergent adverse events, including hematologic toxicities related to gemcitabine and oxaliplatin, were broadly in line with expectations for the chemotherapy backbone. Importantly, treatment-related discontinuation rates remained relatively low in the experimental arm, supporting the real-world feasibility of the regimen in older and comorbid patient populations that often characterize transplant-ineligible diffuse large B-cell lymphoma.

Clinicians have also emphasized the operational advantage of Columvi as an off-the-shelf antibody. Unlike CAR-T therapies, which require complex leukapheresis, manufacturing delays, and inpatient monitoring, Columvi can be initiated rapidly after relapse confirmation. This feature is particularly important in aggressive lymphomas characterized by fast disease progression, where weeks of delay can materially impact outcomes.

How does Roche’s Columvi strategy compare with CAR-T and emerging bispecific competition in aggressive lymphoma?

The long-term STARGLO data arrive in an increasingly competitive therapeutic landscape. CAR-T cell therapies from multiple manufacturers have established deep and durable responses in relapsed diffuse large B-cell lymphoma, but access remains constrained by manufacturing capacity, high cost, and strict patient eligibility criteria. In parallel, several pharmaceutical companies are advancing competing CD20xCD3 bispecific antibodies with varying dosing schedules and safety profiles.

Roche’s strategy with Columvi differentiates on several fronts. First, the fixed-duration regimen contrasts with some competing bispecifics that require continuous administration until progression. Second, the robust three-year overall survival advantage over Rituxan-based chemotherapy provides a high evidentiary bar for peers attempting to displace Columvi in the transplant-ineligible segment. Third, Roche continues to run a broad clinical development program that explores Columvi in earlier-line diffuse large B-cell lymphoma, in combination with standard immunochemotherapy backbones, and across other B-cell malignancies.

At the same time, regulatory risk remains part of the investment narrative. In the United States, the Food and Drug Administration previously issued a complete response letter for the Columvi plus gemcitabine and oxaliplatin supplemental application seeking expansion into earlier-line settings. Regulators expressed concerns about the applicability of the STARGLO population to U.S. treatment practices and requested additional confirmatory evidence. While Columvi has already secured approvals in multiple international markets, the U.S. regulatory pathway remains strategically important given the size of the domestic lymphoma market.

Roche has indicated that it remains engaged with regulators and continues to generate real-world and trial-based evidence designed to address those concerns. The three-year dataset adds weight to those efforts by demonstrating that early survival gains are not eroded over time.

How is investor sentiment toward Roche evolving as Columvi strengthens its long-term revenue visibility?

From a capital-markets perspective, the three-year STARGLO update reinforces Columvi as a durable growth pillar within Roche’s hematology portfolio at a time when the company is actively managing patent expirations in other franchises. Roche Holding AG trades in the United States under the OTC symbol RHHBY, and the stock has generally reflected a defensive large-cap pharmaceutical profile, with investors focusing on earnings stability, dividend yield, and pipeline durability rather than high-beta growth.

Market sentiment toward RHHBY has been broadly neutral to cautiously positive in recent months, shaped by steady oncology cash flows, expanding diagnostics revenues, and ongoing restructuring efforts aimed at improving margin efficiency. The strengthening Columvi data inject an element of medium-term growth optionality into that otherwise conservative narrative. Analysts increasingly view bispecific antibodies as one of the fastest-growing segments within hematologic oncology, with potential to capture market share from both chemotherapy and CAR-T therapies.

Revenue visibility for Columvi could improve meaningfully if additional regulatory milestones are secured, especially in the United States. Even under current international approvals, continued label penetration and earlier-line adoption could translate into multi-billion-dollar peak-sales potential over time. For income-oriented investors who favor Roche for its dividend track record, Columvi provides a pipeline-driven growth lever that supports long-term payout sustainability.

Short-term share price movements in RHHBY have remained tied more closely to broader pharmaceutical sector sentiment and macroeconomic conditions than to single-asset clinical updates. However, sustained accumulation of positive long-term data across Roche’s oncology pipeline, including Columvi, contributes incrementally to valuation support and downside protection.

What does the three-year STARGLO readout signal for the future standard of care in relapsed diffuse large B-cell lymphoma?

The latest STARGLO survival data underscore a broader structural shift in lymphoma treatment away from traditional chemoimmunotherapy toward immune-engaging biologics that deliver deeper and more durable remissions. Columvi’s sustained three-year overall survival advantage over Rituxan-based therapy positions it as a legitimate new backbone for transplant-ineligible relapse, rather than a niche salvage option.

Clinical practice guidelines in several regions have already begun incorporating bispecific antibodies more prominently, and the weight of long-term survival evidence is likely to further accelerate that trend. For patients, this evolution translates into expanded access to high-efficacy immunotherapy without the logistical barriers of cellular manufacturing. For health systems, it offers a potentially more predictable and scalable treatment model compared with inpatient-intensive CAR-T programs.

For Roche, the STARGLO follow-up serves as a strategic validation of its long investment in bispecific antibody engineering and immune-engagement platforms. The company now holds one of the most mature datasets in this therapeutic class, with survival durability extending well beyond the two-year mark that often defines early oncology success.

As additional analyses mature and real-world evidence continues to accumulate, Columvi is likely to play a central role in shaping the next decade of diffuse large B-cell lymphoma management. While regulatory hurdles in the United States still represent an overhang, the clinical foundation for long-term adoption is now firmly established.